---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-090634"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2021-07-09T23:59:59+00:00"
generated_at: "2026-06-30T06:23:24.035308+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics names C. Russell Trenary III CEO; Lawrence Kenyon stays CFO

## Summary
- C. Russell Trenary III appointed President & CEO effective July 6, 2021; replaces Lawrence Kenyon who remains CFO.
- Base salary $600,000; target annual cash bonus of 70% of base salary.
- Received initial grant of 4,000,000 options + performance grant of 1,000,000 options with milestone vesting.
- Company on track for NORSE TWO top-line data Q3 2021; plans BLA submission for ONS-5010 in Q1 2022.
- Trenary previously led InnFocus through acquisition by Santen; over 35 years in life sciences.

## SEC filing metadata
- accession: 0001104659-21-090634
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2021-07-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/tm2121712d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-090634
- JSON: https://secwatch.observer/filing/0001104659-21-090634.json
- Plain text: https://secwatch.observer/filing/0001104659-21-090634.txt

## Key facts
- Executive change
  Lawrence Kenyon resigned as Chief Financial Officer at Outlook Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Trenary replaces Lawrence Kenyon, who resigned as President and Chief Executive Officer of the Company concurrently with Mr. Trenary’s appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm
- Executive change
  C. Russell Trenary III was appointed as President and Chief Executive Officer at Outlook Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On July 6, 2021, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) appointed C. Russell Trenary III as President and Chief Executive Officer of the Company and as a director, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465921090634/0001104659-21-090634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.